TMCnet

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

VYVGART was well-tolerated with a safety profile consistent with the established profile of VYVGART in patients with AChR-Ab seropositive gMG and other indications. No new safety concerns were ...

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531)

Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
Pharmabiz

European Commission approves Sanofi’s Teizeild to treat patients with stage 2 type 1 diabetes

European Commission approves Sanofi’s Teizeild to treat patients with stage 2 type 1 diabetes: Paris Tuesday, January 13, 2026, 11:00 Hrs [IST] The European Commission has appro ...

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...
The Malaysian Reserve

Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Heal…

Reports positive early clinical experience from first and only clinically validated, extracellular protein degraders using ...

Press Release: Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes

Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetesApproval based on the TN-10 phase 2 study that demonstrated a ...
EuropaWire

Sanofi Secures European Approval for Disease-Modifying Type 1 Diabetes Therapy

The European Commission has approved Sanofi’s Teizeild as the first disease-modifying therapy in the EU to delay the onset of stage 3 type 1 diabetes in adults and children with stage 2 T1D. Supported ...